lowered shares of TrovaGene (NASDAQ:TROV) from a buy rating to a hold rating in a research note issued to investors on Wednesday, November 15th.
Other analysts have also recently issued reports about the company. Maxim Group set a $4.00 price target on TrovaGene and gave the stock a buy rating in a report on Wednesday, October 18th. Cantor Fitzgerald reaffirmed an overweight rating on shares of TrovaGene in a report on Tuesday, August 8th.
TrovaGene (TROV) traded down $0.05 during trading hours on Wednesday, reaching $0.55. The company’s stock had a trading volume of 356,804 shares, compared to its average volume of 560,072. TrovaGene has a 1 year low of $0.55 and a 1 year high of $2.85.
TrovaGene (NASDAQ:TROV) last posted its quarterly earnings results on Thursday, November 9th. The medical research company reported ($0.12) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.02. TrovaGene had a negative return on equity of 259.94% and a negative net margin of 7,960.05%. The firm had revenue of $0.12 million during the quarter.
A number of hedge funds have recently bought and sold shares of the stock. KCG Holdings Inc. grew its holdings in shares of TrovaGene by 560.1% in the first quarter. KCG Holdings Inc. now owns 210,301 shares of the medical research company’s stock valued at $242,000 after acquiring an additional 178,440 shares in the last quarter. LMR Partners LLP bought a new position in TrovaGene during the second quarter valued at $151,000. Goldman Sachs Group Inc. boosted its holdings in shares of TrovaGene by 1,079.5% in the second quarter. Goldman Sachs Group Inc. now owns 278,186 shares of the medical research company’s stock worth $351,000 after acquiring an additional 254,601 shares during the period. Finally, Susquehanna International Group LLP boosted its holdings in shares of TrovaGene by 2,781.0% in the second quarter. Susquehanna International Group LLP now owns 138,031 shares of the medical research company’s stock worth $174,000 after acquiring an additional 133,240 shares during the period. 13.92% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “TrovaGene (TROV) Stock Rating Lowered by” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.dispatchtribunal.com/2017/12/04/trovagene-inc-trov-lowered-to-hold-at.html.
Trovagene, Inc is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers.
Receive News & Ratings for TrovaGene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene Inc. and related companies with MarketBeat.com's FREE daily email newsletter.